No B shares were repurchased and a total of 500 treasury shares were sold to Novo Nordisk employees in relation to existing incentive programmes during the second quarter of 2001.
This announcement is pursuant to Section 204.33, Treasury Stock Changes, of the New York Stock Exchange Listed Company Manual.
This announcement is pursuant to Section 204.33, Treasury Stock Changes, of the New York Stock Exchange Listed Company Manual.
Novo Nordisk is a focused healthcare company and the world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as coagulation disorders, growth disorders and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 14,000 people in 68 countries and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADSs are listed on the New York Stock Exchange under the symbol 'NVO'.
For further company information visit www.novonordisk.com
For further company information visit www.novonordisk.com
For further information please contact:
Media
Outside North America:
Elin K Hansen
Tel (direct): (+45) 4442 3450
Outside North America:
Elin K Hansen
Tel (direct): (+45) 4442 3450
In North America:
Susan Toth Jackson
Tel: (+1) 212 867 0123
Susan Toth Jackson
Tel: (+1) 212 867 0123
Investors
Outside North America:
Peter Haahr
Tel (direct): (+45) 4442 1207
Outside North America:
Peter Haahr
Tel (direct): (+45) 4442 1207
In North America:
Rasmus Jorgensen
Cell phone: (+1) 917 945 4640
Rasmus Jorgensen
Cell phone: (+1) 917 945 4640
Stock Exchange Announcement No 10 / 2001